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Figure 1 Partial pedigree of the family. Filled symbols denote affected subjects; open symbols denote asymptomatic subjects; oblique line
denote deceased. Numbers beside symbols are subject identifiers. The ages of unaffected individuals are indicated. For affected subjects, the
tumor type and the age at diagnosis or of death (in parentheses) are indicated. Ca p cancer; y p years; mo p months.
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Early-Onset Brain Tumor and Lymphoma in MSH2-
Deficient Children
To the Editor:
Homozygous germline mutations of MLH1 have been
reported so far in three families with hereditary non-
polyposis colorectal cancer (HNPCC [MIM 114500])
and have been shown to be associated with leukemia or
lymphoma, CNS tumors, and the neurofibromatosis type
I phenotype (Ricciardone et al. 1999; Wang et al. 1999;
Vilkki et al. 2001). More recently, the first case of a
homozygous germline mutation ofMSH2 was described
in a child with leukemia and multiple cafe´-au-lait spots
(Whiteside et al. 2002). We report here the incidental
discovery of a new case of MSH2 deficiency, which is
remarkable because of the presentation of the family and
because of the association with an early-onset brain
tumor.
The proband (III.2) and her husband (III.1), of French
origin, were seen for genetic counseling in the dramatic
context of the death of their two children (fig. 1). In-
dividual IV.1 died at age 15 mo from a T mediastinal
lymphoma; her brother (IV.2) died at age 4 years from
a temporal glioblastoma. Their mother and father, age
29 years and 32 years, respectively, had no personal
history of cancer. Although several second-degree rela-
tives of the parents had developed cancers (fig. 1), the
presentation of the family did not fulfill the criteria for
a Mendelian genetic predisposition to cancer. The de-
velopment of a CNS tumor and lymphoma in two sibs
led us to consider initially the hypothesis of Li-Fraumeni
syndrome (LFS) in this family. Since no DNA was avail-
able from the affected children, we analyzed the TP53
gene in both unaffected parents. Sequencing analysis of
TP53 revealed no mutation. Stimulated by our recent
finding of a family with LFS with complete heterozygous
germline deletion of TP53 (unpublished data), we com-
pleted the analysis of TP53 by searching for a similar
defect using quantitative multiplex PCR of short fluo-
rescent fragments (QMPSF) (Charbonnier et al. 2000,
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Figure 2 Detection of the MSH2 alterations. A, Heterozygous deletion of MSH2 exons 1–6 in the father (individual III.1) detected by
QMPSF. The electropherogram of the father (red) was superposed on that of a control individual (blue). The Y-axis displays fluorescence in
arbitrary units, and the X-axis indicates the size in bp. This result was obtained on two independent samples. B, Heterozygous 1-bp deletion
within exon 3 detected in the mother (individual III.2). C, Hemizygous 1-bp deletion within exon 3, detected in the brain tumor developed in
individual IV.2. In panels B and C, sequences correspond to the noncoding strand.
2002). QMPSF analysis of TP53 performed in the father
(III.1) demonstrated that the TP53 gene was not af-
fected, but, to our surprise, revealed a heterozygous de-
letion of MSH2 exon 3 corresponding to the control
amplicon. Therefore, we analyzed, by QMPSF, the 16
exons of MSH2, and this analysis showed the presence,
in the unaffected father, of a heterozygous genomic de-
letion of MSH2 removing exons 1–6 (fig. 2A). We then
sequenced the MSH2 gene in the unaffected mother
(III.2) and identified a 1-bp heterozygous deletion at co-
don 153 within exon 3 (fig. 2B). In the absence of con-
stitutional DNA from the affected children, we se-
quenced MSH2 exon 3 from the glioblastoma DNA of
individual IV.2. As shown in figure 2C, we detected only
the mutant maternal allele, which strongly suggested
that individual IV.2 had received from his father the
mutant allele harboring the exons 1–6 deletion. Haplo-
type analysis at the MSH2 locus confirmed the presence
of two parental MSH2 alleles within the tumor, ruling
out a somatic loss of heterozygosity (data not shown).
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Screening for microsatellite instability (MSI), as rec-
ommended by Boland et al. (1998), revealed no repli-
cation error (RER) phenotype within the glioblastoma.
This case report shows that MSH2 deficiency in hu-
mans can result in early-onset CNS tumors. Homozy-
gous MLH1 mutations have been detected in two chil-
dren who had developed a medulloblastoma (Wang et
al. 1999) and a glioma (Vilkki et al. 2001). Compound
heterozygous mutations of the PMS2 gene, which is
rarely involved in HNPCC, have been identified in two
sisters with early-onset brain and colorectal tumors (De
Rosa et al. 2000). These studies, together with the pre-
sent report, indicate that germline MMR deficiency pre-
disposes to primary early-onset neuroepithelial tumors.
Turcot syndrome (MIM 276300) was originally defined
by the association of CNS malignant tumors with fa-
milial polyposis of the colon, but molecular studies have
subsequently distinguished two entities, resulting from
APC and MMR gene mutations, respectively (Hamilton
et al. 1995; Paraf et al. 1997). It is tempting to speculate,
as suggested elsewhere (De Rosa et al. 2000), that, in
some families with Turcot syndrome, the association of
colorectal neoplasms with childhood brain tumors may
be due to a complete MMR deficiency.
We were surprised that we could not detect an RER
phenotype in the MSH2-deficient brain tumor. It is in-
teresting that MSI was not also detected in the non-
tumoral DNA of the MSH2-deficient patient reported
by Whiteside et al. (2002), in contrast to the case of the
two MLH1-deficient subjects analyzed by Wang et al.
(1999) and Vilkki et al. (2001). This result could suggest
that, at least in certain tissues, MSH2 deficiency could
lead to tumorigenesis through amechanism distinct from
a defect in the repair of postreplicative mismatches af-
fecting repetitive sequences. Indeed, MSH2, like its bac-
terial homolog, MutS, has been shown to play additional
roles in genetic recombination, since these proteins pre-
vent exchange between divergent DNA sequences (Mod-
rich and Lahue 1996). Furthermore, MSH2 was recently
shown to be associated with TP53 within recombinative
repair complexes during S phase (Zink et al. 2002).
As in the previous report of a MSH2 deficiency
(Whiteside et al. 2002), the familial history presented in
this study was not strongly suggestive of HNPCC, al-
though the young age of the parents and their sibs could
explain the absence of cancer within this generation.
Therefore, as shown in this report, the presence of ho-
mozygous mutations of the different MMR genes must
be considered in families with early-onset CNS tumors
and hematological malignancies, even in the absence of
a familial history of HNPCC.
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